Page 2 - Pathogendx Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

PathogenDx Receives CE-IVD Mark for Its Microarray-Based DetectX-Rv Test for COVID-19

PathogenDx Receives CE-IVD Mark for Its Microarray-Based DetectX-Rv Test for COVID-19
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesPathogendx incEuropean union in vitro diagnostic directiveDrug administrationDetectx rv microarray assayEmergency use authorizationDetect cv cladeMilan patelஒன்றுபட்டது மாநிலங்களில்ஐரோப்பிய தொழிற்சங்கம் இல் விட்ரோ கண்டறியும் உத்தரவுஅவசரம் பயன்பாடு அங்கீகாரம்மிலன் படேல்

Flatiron Venture Partners

Flatiron Venture Partners
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Robert wolfPathogendx incPanther opportunity fundCannabis decontamination tech company willow industriesWillow industriesCannabis banking solutions provider green check verifiedWith investors flatiron venture partnersRobert wolf andCheck verifiedFlatiron ventureCresco capitalAltitude investment managementArcadian investment partnersWelcan capitalHalley venture partnersராபர்ட் ஓநாய்

DNA Microarray Market (2021-2025) | Global Demand for DNA Microarray Heightens as Cancer Diagnostics Remains a Hotspot for R&D, Says Fairfield Market Research

DNA Microarray Market (2021-2025) | Global Demand for DNA Microarray Heightens as Cancer Diagnostics Remains a Hotspot for R&D, Says Fairfield Market Resea

United statesUnited kingdomCity ofAsia pacificPathogendx incResearch newswireSee campaignAffymetrix incIllumina incFairfield market researchIncluding fullWitnessing significant demandEarly cancer diagnosisPurchase query click herePacific providesNorth american

DNA Microarray Market (2021-2025) | Global Demand for DNA Microarray Heightens as Cancer Diagnostics Remains a Hotspot for R&D, Says Fairfield Market Research

DNA Microarray Market (2021-2025) | Global Demand for DNA Microarray Heightens as Cancer Diagnostics Remains a Hotspot for R&D, Says Fairfield Market Research
sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomCity ofAsia pacificPathogendx incResearch newswireSee campaignAffymetrix incIllumina incFairfield market researchIncluding fullWitnessing significant demandEarly cancer diagnosisPurchase query click herePacific providesNorth american

PathogenDx Launches Breakthrough Clade Variant Testing and Secures Phase Two Funding as NIH Aims to Increase Capabilities for Viral Mutation Screenings

PathogenDx Launches Breakthrough Clade Variant Testing and Secures Phase Two Funding as NIH Aims to Increase Capabilities for Viral Mutation Screenings News provided by Share this article Share this article SCOTTSDALE, Ariz., March 3, 2021 /PRNewswire/ PathogenDx, Inc., an Arizona based technology company which has developed a multiplexed microarray DNA-based pathogen testing platform, announced today the launch of their Clade Variant Adaptive Surveillance (CVAS) technology to identify SARS-CoV-2 variants in as little as four hours. PathogenDx has also entered phase two funding under the Rapid Acceleration of Diagnostics (RADx) Tech program. The additional funding will be used to support Clade Variant Array screening nationally, initially as an RUO (research use only) release, as well as expand pooled COVID-19 testing with its Detect-Rv test kits for schools, businesses and communities nationwide.

United statesSouth africaUnited kingdomSouth africanPathogendx incNational institute of healthHuman servicesBiomedical advanced researchNational institutes of healthNational institutes of biomedical imagingDevelopment authorityDepartment of healthClade variant adaptive surveillanceClade variant arrayClade arrayClade variant